App No.: Not Yet Assigned Inventor: Jeffrey P. Gilbard

Title: EPA AND DHA ENRICHED OMEGA-3 SUPPLEMENT FOR THE TREATMENT OF DRY EYE, MEIBOMIANITIS AND

Docket No.: AVR-005

XEROSTOMIA

Figure 1

DHA Biosynthesis (N-3 Pathway) a-Linolenic Acid [18:3n-3] [9, 12, 15] delta 6 desaturation Octadecatetraenoic Acid [18:4n-3] [6, 9, 12, 15] elongation Eicosatetraenoic Acid [20:4n-3] [8, 11, 14, 17] delta 5 desaturation Eicosapentaenoic Acid (EPA) [20:5n-3] [5, 8, 11, 14, 17] clongation Docosapentaenoic Acid [22:5n-3] [7, 10, 13, 16, 19] elongation Tetracosapentaenoic Acid [24:5n-3] [9, 12, 15, 18, 21] delta 6 desaturation Tetracosahezaenoic Acid [24:6n-3] [6, 9, 12, 15, 18, 21] beta-oxidation Docosahexaenoic Acid (DHA) [22:6n-3] [4, 7, 10, 13, 16, 19]

Sheet 2 of 2

App No.: Not Yet Assigned Inventor: Jeffrey P. Gilbard

Title: EPA AND DHA ENRICHED OMEGA-3 SUPPLEMENT

FOR THE TREATMENT OF DRY EYE, MEIBOMIANITIS AND XEROSTOMIA

Docket No.: AVR-005

Figure 2

AA Biosynthesis (N-6 Pathway) Linoleic Acid [18:2n-6] [9, 12] delta 6 desaturation Gamma-Linolenic Acid [18:3n-6] [6, 9, 12]elongation Dihomo-Gamma-Linolenic Acid [20:3n-6] [8, 11, 14] delta 5 desaturatiom Arachidonic Acid (AA) [20:4n-6] [5, 8, 11, 14] clongation Docosatetraenoic Acid [22:4n-6] [7, 10, 13, 16] delta 4 desaturation Docosapentaenoic Acid [22:5n-6] [4, 7, 10, 13, 16]